Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.

Nakul Katyal,Karen Halldorsdottir,Raghav Govindarajan,Perry Shieh,Suraj Muley, Phoebedel Reyes,Kenneth K Leung,Jeffrey Mullen,Shadi Milani-Nejad,Manisha Korb,Namita A Goyal,Tahseen Mozaffar,Neelam Goyal,Ali A Habib,Srikanth Muppidi

Muscle & nerve（2023）

引用 0|浏览7

暂无评分

摘要

Efgartigimod led to clinically meaningful improvement in MG-ADL in diverse AChR+ve gMG patients but treatment frequency to achieve optimal symptom control needs to be explored.

查看译文

关键词

acetylcholine receptor antibody positive, efgartigimod, generalized myasthenia gravis, neonatal fc receptor antagonist, neuromuscular junction disorders

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要